From the current study, we concluded that MCH can be used as a screening tool to differentiate the type of β-thalassemia mutation (β0 or β+) in populations of carriers consisting of relatives of patients with thalassemia in South Sumatra. This evidence concerns the gene PMCH and thalassemia.